Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.…
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
Psyence Biomedical (NASDAQ: PBM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 2.970 USD on 20 November 2026, down 97.0% over 52 weeks. Its 52-week range is 1.920 USD to 116.41 USD: the price is 97.4% below the high and 54.7% above the low.
Its market capitalisation is 11.33M USD.
Psyence Biomedical reports return on equity of -40.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.44M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.